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Copyright © 200? JCBN Summary Citrus bioflavonoids may offer some protection against the early stage of diabetes
mellitus and the development of complications. We investigated the effect of hesperidin on
blood glucose levels, hepatic glucose-regulating enzyme activities, serum insulin and adiponectin
levels, serum and hepatic lipid levels, and parameters of bone loss in streptozotocin (STZ)-
induced marginal type 1 diabetic rats. Weanling male rats were randomly assigned to experi-
mental 3 groups: a control (C) group, a STZ induced marginal type 1 diabetes (S) group, and
a diabetes and hesperidin group, and fed their respective diets for 4 weeks. STZ injection
increased blood glucose in rats, but the increase was marginal. Serum and hepatic lipids,
serum adiponectin and insulin levels were significantly changed by STZ injection. Dietary
hesperidin (10 g/kg diet) decreased blood glucose by altering the activity of glucose-regulating
enzymes, and normalized the lipids and adiponectin levels, but did not change bone para-
meters in the marginal type 1 diabetic rats. Hesperidin showed both hypoglycemic and hypo-
lipidemic effects but did not affect bone tissue and bone metabolic makers in STZ-injected
marginal diabetic weanling rats without any body weight loss due to STZ injection.
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Introduction
Diabetes is the most common serious metabolic disorder,
and it is considered to be 1 of the 5 leading causes of death
in the world [1]. Hyperglycemia can be initially treated with
oral agents and insulin therapy; the latter is occasionally
required to achieve target glycemic levels. Moreover, dia-
betes is associated with increased risk of thrombotic, athero-
sclerotic and cardiovascular disease [2]. Dyslipidemia is a
frequent complication of diabetes and is characterized by
low levels of high-density lipoprotein (HDL)-cholesterol, and
high levels of low-density lipoprotein (LDL)-cholesterol
and triglycerides (TGs). Hyperlipidemia is also a metabolic
complication of both clinical and experimental diabetes. In
addition, it is well known that diabetes can affect bone
remodeling by various mechanisms, including deficient
insulin action, increased accumulation of advanced glyca-
tion end-products and microangiopathy, although the clinical
manifestations of diabetic osteopathy are not fully under-
stood. Type 1 diabetic patients are at high risk for bone loss
and bone fracture. One of the mechanisms of diabetes-
related bone diseases may be oxidative damage to osteo-
blasts. Flavonoids are present in several types of vegetables
and fruits, and may be associated with potential health
benefits [3–4]. Hesperidin, a citrus bioflavonoid, exhibitsS. Akiyama et al.
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biological and pharmacological properties such as anti-
inflammatory, anti-carcinogenic, antioxidative, and lipid-
lowering activities [5–7]. Furthermore, we demonstrated
that hesperidin not only has cholesterol-lowering effects but
also prevents bone loss in ovariectomized (OVX) mice,
without exerting any substantial effects on the uterus [7].
Recently, Choi and Kim reported that hesperetin, the agly-
cone of hesperidin, can act as a biological antioxidant in a
cell culture system representative of a diabetic state and
protect osteoblasts from oxidative stress-induced toxicity,
which may promote bone recovery in diabetic bone diseases
[8]. However, the in vivo effects of hesperidin and hesperetin
on type 1 diabetic animals remain unknown. In the present
study, we investigated the hypoglycemic and hypolipidemic
effects of hesperidin, and the effect of hesperidin on bone
status in streptozotocin (STZ)-induced type 1 diabetic rats.
However, since the body weights of STZ-induced type 1
diabetic rats are decreased [9, 10], the hypolipidemic effects
of phytochemicals may not indicate in such a severe type 1
diabetic model. We used marginal type 1 diabetic rats, which
the body weight was similar with the control rats in this
study.
Materials and Methods
Experimental Design and Sample Treatments
Eighteen 3-week-old male Wistar rats (Clea Japan, Tokyo,
Japan) were individually housed in stainless-steel rat cages
at 22°C and maintained under a 12-h light/12-h dark cycle.
The Animal Use Committee of the Tokyo University of
Agriculture approved the study, and the animals were
maintained in accordance with the guidelines of the univer-
sity for the care and use of laboratory animals. For a 3-day
acclimatization period, all rats were fed a control diet that
was based on the AIN-93G diet and prepared with corn oil
instead of soybean oil. After this period, the rats were
randomly assigned to 3 experimental groups consisting of 6
rats each: control (C) group, type 1 diabetes (S) group, and
type 1 diabetes and hesperidin (SH) group. Rats in the S
and SH groups received 2 intraperitoneal (ip) injections of
STZ (70 mg/kg body weight; Sigma-Aldrich Co., MO) in a
vehicle (0.9% NaCl), and the control rats received ip
injections of vehicle alone. Starting at 3 days after the ip
injections, the C and S group rats were fed a control diet,
and the SH group rats were fed a hesperidin-containing
diet (10 g/kg diet) for 4 weeks. We previously have dosed
hesperidin containing diet (5 g/kg diet) to OVX mice [7].
In the same time, as a pilot study, we indicated that 1%
hesperidin (10 g/kg diet) was needed in rats for inhibiting
bone loss and due to magnesium-deficiency (unpublished
data). Moreover, Horcajada et al. suggested that the effective
dose of hesperetin on bone and lipids in rats was 0.5% in the
diet [11]. This dosage of hesperetin can be calculated around
1% as hesperidin. Thus, the dosage of 1% (10 g/kg diet)
hesperidin in the diet was also employed for this study. All
rats were given free access to distilled water. After 4 weeks
of feeding, all rats were sacrificed, and blood and liver
samples were collected for analysis. The blood samples
were centrifuged, and the supernatants were used as serum
samples. Urine was collected during the 24 h prior to dis-
section. Serum and urine samples were stored at −80°C until
analysis. The liver was perfused with cold 0.9% NaCl
solution and then removed. The femur and tibia were
removed, cleansed of all soft tissues and stored in 70%
ethanol solution at 4°C until analysis. The lumbar vertebrae
were removed, cleansed of all soft tissues and frozen at
−80°C until analysis.
Measurements of blood glucose, serum insulin and
adiponectin, serum and hepatic lipids, and serum and
urinary bone metabolic markers
Blood glucose concentration was measured during the
acclimatization period, at 3 days after the ip injections, and 1
day prior to dissection. Samples were collected from the tail
vein after the animals had been fasted for 12 h, and glucose
concentrations were measured with a blood glucose meter
(Medisafe-mini GR-102; Terumo Co., Tokyo, Japan). Serum
insulin, serum adiponectin, serum and hepatic lipids, serum
and urinary bone metabolic markers and urinary creatinine
levels were measured with commercial kits (Rat Insulin
ELISA Kit and Mouse/Rat High Molecular Adiponectin
ELISA Kit, Shibayagi, Gunma, Japan); cholesterol C test,
triglyceride E test and HDL cholesterol test (Wako Pure
Chemicals); Osteocalcin rat ELISA system (Amersham
Pharmacia Biotech, Buckinghamshire, UK); Metra DPD
(Quidel Co., San Diego, CA); RatLaps ELISA (Norbic
Bioscience Diagnostics A/S, Herlev, Denmark); and
Creatinine-test Wako (Wako Pure Chemicals, Osaka, Japan).
Measurement of serum hesperetin concentration
Serum hesperetin concentration was measured using high-
performance liquid chromatography (HPLC) with electro-
chemical detection (Chrochem 2; ESA, Chelmsford, MA)
and UV detection (SPD-10A; Shimazu, Tokyo, Japan), as
described, previously [7].
Measurements of hepatic enzymes
Glucokinase (GK) and Glucose-6-phosphatase (G6Pase)
activities in liver microsomes was determined as described
by Davidson and Arion [12], and according to the method of
Bickerstaff and Burchell [13], respectively.
Measurements of bone mineral contents and bone mineral
density
Bone samples from each rat were used for analysis of
bone mineral content (BMC) and bone mineral densityHesperidin and Marginal Type 1 Diabetic Rats
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(BMD) by dual-energy X-ray absorptiometry (DXA; model
DCS- 600R; Aloka, Tokyo, Japan). BMD was calculated on
the basis of the BMC of the measured area.
Statistics
The results were expressed as the mean ± SEM for each
group of 6 rats. After one-way analysis of variance
(ANOVA), Fisher’s protected least significant difference
(PLSD) test was used to determine significant differences.
Differences were considered significant at p<0.05.
Results
Body weight and food intake
The initial and final body weights (54 g and 242–247 g,
respectively), and mean food intake during the feeding
period (16 g/day) did not differ among the 3 groups. Average
of hesperidin intake was 160 mg/day.
Blood glucose and serum insulin concentrations
Three days after the ip injections, blood glucose was
significantly higher in the S and SH groups than in the C
group, although the increase of blood glucose by STZ
injection was marginal. However, the final blood glucose
concentration was significantly decreased in the SH group
compared with that in the S group (Table 1). The serum
insulin concentration was the highest in the SH group
(Table 1).
Serum hesperetin concentration
Serum hesperetin detected in the SH (12.3 ± 3.3 μmol/l),
but not in other two groups.
Hepatic GK and G6Pase activities and serum adiponectin
The activity of G6Pase was increased and that of GK was
decreased in STZ-injected rats. In the STZ rats that were
fed the hesperidin diet, the activities of both enzymes had
normalized (Table 1). Serum Adiponectin concentration was
decreased by STZ-injection, but normalized by hesperidin
administration (Table 1).
Serum and hepatic lipids
The serum TG, total cholesterol (TC) and LDL + VLDL
cholesterol concentrations were significantly increased by
STZ injection, but hesperidin suppressed the increase in
these levels (Table 2). Serum HDL-cholesterol concentra-
tion and HDL/TC ratio were lower in the S group than in the
C and SH groups. The hepatic TG and TC concentrations
Table 1. Blood glucose, serum insulin and adionectin levels, and activities of hepatic glucose regulating enzymes
G6Pase, Glucose-6-phosphatase; GK, Glucokinase. Values are means ± SEM, n = 6. C, Control group; S, STZ injected group; SH,
STZ + hesperidin group. Means without a common letter differ, p<0.05.
Group C S SH
Blood glucose (mg/dl)
Acclimatization period 96.66 ± 8.57 98.00 ± 7.29 95.16 ± 6.66
3 days after the ip injections 91.33 ± 6.38b 120.50 ± 7.97a 121.50 ± 5.89a
1 day prior to dissection 89.33 ± 5.11b 131.67 ± 5.02a 94.36 ± 4.77b
Insulin (ng/ml) 1.77 ± 0.58b 0.91 ± 0.47b 4.03 ± 1.22a
G6Pase (μmol/min/mg protein) 518.09 ± 55.45b 774.88 ± 72.28a 288.86 ± 68.02c
GK (μmol/min/mg protein) 322.63 ± 47.52a 191.35 ± 22.93b 370.82 ± 30.06a
Adiponectin (ng/ml) 351.93 ± 71.09a 188.34 ± 23.98b 327.69 ± 42.70a
Table 2. Serum and hepatic lipids
Values are means ± SEM, n = 6. C, Control group; S, STZ injected group; SH, STZ + hesperidin group. Means without a common
letter differ, p<0.05.
Group C S SH
Serum TG (mg/dl) 99.53 ± 6.55b 136.41 ± 9.42a 110.89 ± 6.02b
Serum TC (mg/dl) 65.76 ± 2.60b 76.05 ± 4.29a 65.59 ± 4.25b
Serum HDL-C (mg/dl) 46.57 ± 1.20a 36.08 ± 2.43b 47.97 ± 1.95a
Serum LDL + VLDL-C (mg/dl) 19.19 ± 2.41b 39.97 ± 4.89a 17.62 ± 3.01b
HDL-C/TC 0.71 ± 0.02a 0.48 ± 0.04b 0.73 ± 0.03a
Liver TG (mg/g) 24.28 ± 1.24b 27.38 ± 2.25a 23.40 ± 2.25b
Liver TC (mg/g) 2.56 ± 0.06b 3.12 ± 0.10a 2.04 ± 0.10cS. Akiyama et al.
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were also significantly increased in the S group, but in the
SH group, hesperidin suppressed this increase (Table 2).
BMC and BMD in femur, tibia and limbar, and bone meta-
bolic markers
The femoral BMD and BMC, and the levels of deoxy-
pyridinoline (DPD) and C-telopeptide of type 1 collagen
(CTx), which are markers of bone resorption, were not
altered by STZ injection. Only osteocalcin, a marker of
bone formation, was decreased in the STZ-injected groups,
but there was no significant difference in the osteocalcin
levels between the S and SH group rats (Table 3).
Discussion
Although the dose of STZ to the rats was high (70 mg/kg
BW), blood glucose level was not particularly increased in
this study. It seems that STZ-injection was failed. Therefore,
this dose of STZ was slightly but significantly increased
blood glucose, and changed enzymes related with glucose
metabolism without any change in body weight and food
intake. In other words, in marginal status of diabetes, the rats
were fed the hesperidin diet in this study. Regarding normal
rats, there were no effects of hesperidin administration on
serum and hepatic lipids in weanling Sprague-Dawley male
rats, and on serum glucose in aging Wistar male rats in
our pilot studies (data is not shown), while plasma total
cholesterol and triglyceride concentrations showed lower
values in hesperidin-treating sham operated (SH) female
Wistar rats than in the SH control rats (6 and 9 month-old )
from the study of Horcajada et al. [ 11]. Many studies
have shown that some flavonoids and other phytochemicals
decrease blood glucose levels and oxidative stress, and
increase serum insulin concentrations [3–5,  14–16]. One
of the reasons flavonoids ameliorate diabetes might be
alterations in the activity of key enzymes involved in
glucose metabolism. It is reported that hesperidin and
naringin increase the mRNA level of GK, a key enzyme of
glucose catabolism, and decrease the level of G6Pase, a
gluconeogenic enzyme, in type 2 diabetic mouse liver [17].
In this study, the activities of both GK and G6Pase were
also changed in STZ-injected rats. In contrast, in the STZ
rats that were fed the hesperidin diet, the activities of
both enzymes had normalized, and the insulin levels had
increased; this has been previously reported in type 2
diabetic mice, but not in type 1 diabetic rodents. Adiponectin,
a metabolically active protein secreted by adipocytes, plays
an important role in the regulation of glucose and lipid
metabolism, and modifies insulin sensitivity and energy
balance [18, 19]. In this study, the serum insulin level was
increased, and the blood glucose level was decreased on
hesperidin administration to the STZ-injected rats. Hesperidin
might inhibit the damage of pancreatic islet by the antioxida-
tive efficacy, and the treatment with hesperidin might
increase insulin and consequently decrease glucose levels
and alter glycogen contents in the diabetic tissues due to
improving glycolytic and gluconeogenetic enzymes like as
rutin [16]. However, hesperidin administration showed
beyond the control level of insulin. We analyzed serum
hesperetin value and the mean concentration of the SH
group was 12.3 μmol/L, while it was not detectable in the
control and S groups. It was higher in the SH rats than that
(3.57 μmol/L) in rats from the study of Horcajada et al. [11],
although the dosage of hesperetin (as aglycone) was similar
in the both studies, while strain, age, sex and feeding term
were different. Further, the serum adiponectin concentration
was significantly decreased in the STZ-injected rats, but the
value was normalized by hesperidin administration. Liu
et al. reported that naringenin and hesperetin up-regulated
the transcription of adiponectin and induced the expression
of peroxisome proliferator-activated receptor (PPAR) γ-
controlled luciferase in vitro but not in vivo [ 20]. We
observed the in vivo hypoglycemic and hypolipidemic
effects of hesperidin, which are mediated by increasing
Table 3. Bone mineral contents (BMC), bone mineral density (BMD) and makers of bone turnover
Values are means ± SEM, n = 6. C, Control group; S, STZ injected group; SH, STZ + hesperidin group. Means without a common letter
differ, p<0.05.
Group C S SH
Femur BMC (mg) 184.18 ± 3.26 172.16 ± 6.77 176.40 ± 4.57
BMD (mg/cm2) 100.53 ± 1.19 99.75 ± 2.87 101.01 ± 1.27
Tibia BMC (mg) 139.13 ± 2.74 136.83 ± 4.43 135.53 ± 2.80
BMD (mg/cm2) 83.00 ± 0.85 83.94 ± 1.53 82.38 ± 0.81
Lumbar BMC (mg) 16.56 ± 0.54 16.63 ± 1.29 16.33 ± 0.93
BMD (mg/cm2) 48.36 ± 0.96 46.23 ± 2.09 46.71 ± 1.35
Serum Osteocalcin (ng/ml) 63.72 ± 5.94a 38.05 ± 4.00b 41.78 ± 3.79b
Urinary CTx (μg/mmol creatinine) 24.09 ± 3.31 24.94 ± 2.16 22.75 ± 3.14
Urinary DPD (nmol/mmol creatinine) 727.86 ± 82.64 629.17 ± 106.21 583.96 ± 63.02Hesperidin and Marginal Type 1 Diabetic Rats
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serum adiponectin levels, in rodents.
In this study, hesperidin also showed hypolipidemic effects
in STZ-induced diabetic rats. The serum and hepatic TG,
TC and serum LDL + VLDL cholesterol concentrations were
significantly increased by STZ injection, but hesperidin
suppressed the increase in these levels. In contrast, HDL-
cholesterol concentration and HDL/TC ratio were decreased
by STZ-injection, but were normalized by hesperidin
administration. By using weanling rats that were maintained
for 28 days under conditions that were almost identical to
those in our study, Myake et al. [5] reported that hesperidin
exerts protective effects against oxidative stress but not
against the effects of increased serum glucose and lipid
levels. It is well known that 3-hydroxy-3-methyl- glutaryl-
CoA (HMG-CoA) reductase inhibitors are very effective
in lowering plasma cholesterol in most animal species,
including humans, and these inhibitors are now widely used
as hypocholesterolemic drugs. Bok et al. demonstrated that
in rats, naringin and hesperidin significantly lowered the
plasma and hepatic levels of cholesterol and TG by
inhibiting HMG-CoA reductase and acyl CoA:cholesterol
acyltransferase (ACAT) [21]. Furthermore, hesperidin
enhances expression of the gene encoding the LDL receptor
[22]. These are some possible mechanisms underlying the
hypolipidemic effects of hesperidin; we, however, did not
measure the activities of HMG-CoA reductase and ACAT or
the expression of the gene encoding the LDL receptor. We
demonstrated increasing adiponectin, which can reduce lipid
accumulation, by hesperidin administration.
Previous researchers have reported that STZ-injected
rats exhibit decreased bone formation and increased bone
resorption [23]. In this study, however, the femoral BMD
and BMC, and the levels of bone resorption markers such
as DPD and CTx were not altered by STZ injection. Only
osteocalcin, a marker of bone formation, was decreased
in the STZ-injected groups, but there was no significant
difference in the osteocalcin levels between the S and SH
group rats. As mentioned above, we made a marginal model
of type 1 diabetes. Bone loss was not occurred in this model.
Further, we used weanling rats (aged 4 weeks) in this study,
while other researchers have used adult rats (aged 10–16
weeks). This is another reason why we did not observe bone
loss in the STZ-injected rats in the present study. During the
growing period in rats, STZ does not seem to affect bone
tissue to a great extent. Consequently, only marginal bone
loss was induced, and hesperidin did not affect any bone
parameters in this study. It has been reported [24] that the
flavonol quercetin inhibits bone loss due to STZ-induced
diabetes by using rats aged 16 weeks.
In conclusion, we demonstrated that hesperidin normal-
izes blood glucose by altering the activity of glucose-
regulating enzymes, and lowering serum and liver lipid
levels in STZ-induced marginal type 1 diabetic rats without
any body weight loss due to STZ injection. Thus, hesperidin
showed both hypoglycemic and hypolipidemic effects but did
not affect bone status in marginal type 1 diabetic weanling
rats.
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